SWX:SANN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Santhera Pharmaceuticals Holding

Executive Summary

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. More Details


Snowflake Analysis

Mediocre balance sheet and slightly overvalued.

Share Price & News

How has Santhera Pharmaceuticals Holding's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SANN is more volatile than 75% of Swiss stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: SANN's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Swiss stocks.


Market Performance


7 Day Return

-1.3%

SANN

3.6%

CH Biotechs

0.4%

CH Market


1 Year Return

-78.5%

SANN

1.3%

CH Biotechs

-0.4%

CH Market

Return vs Industry: SANN underperformed the Swiss Biotechs industry which returned 1.3% over the past year.

Return vs Market: SANN underperformed the Swiss Market which returned -0.4% over the past year.


Shareholder returns

SANNIndustryMarket
7 Day-1.3%3.6%0.4%
30 Day-1.3%1.5%2.8%
90 Day-19.9%2.0%5.8%
1 Year-78.5%-78.5%2.6%1.3%3.1%-0.4%
3 Year-93.1%-93.1%4.3%1.9%19.8%4.7%
5 Year-96.2%-96.2%71.8%66.0%51.9%26.8%

Long-Term Price Volatility Vs. Market

How volatile is Santhera Pharmaceuticals Holding's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Santhera Pharmaceuticals Holding undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: SANN (CHF2.7) is trading below our estimate of fair value (CHF210.9)

Significantly Below Fair Value: SANN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: SANN is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.

PE vs Market: SANN is unprofitable, so we can't compare its PE Ratio to the Swiss market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SANN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SANN is overvalued based on its PB Ratio (147.2x) compared to the CH Biotechs industry average (3x).


Next Steps

Future Growth

How is Santhera Pharmaceuticals Holding forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

53.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SANN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SANN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SANN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SANN's revenue (39.3% per year) is forecast to grow faster than the Swiss market (4.6% per year).

High Growth Revenue: SANN's revenue (39.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SANN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Santhera Pharmaceuticals Holding performed over the past 5 years?

-22.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SANN is currently unprofitable.

Growing Profit Margin: SANN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SANN is unprofitable, and losses have increased over the past 5 years at a rate of 22.2% per year.

Accelerating Growth: Unable to compare SANN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SANN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.3%).


Return on Equity

High ROE: SANN has a negative Return on Equity (-11380.95%), as it is currently unprofitable.


Next Steps

Financial Health

How is Santhera Pharmaceuticals Holding's financial position?


Financial Position Analysis

Short Term Liabilities: SANN's short term assets (CHF36.6M) exceed its short term liabilities (CHF30.0M).

Long Term Liabilities: SANN's short term assets (CHF36.6M) do not cover its long term liabilities (CHF69.9M).


Debt to Equity History and Analysis

Debt Level: SANN's debt to equity ratio (27665.2%) is considered high.

Reducing Debt: Insufficient data to determine if SANN's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable SANN has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: SANN is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 11.9% per year.


Next Steps

Dividend

What is Santhera Pharmaceuticals Holding current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SANN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SANN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SANN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SANN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SANN's dividend in 3 years as they are not forecast to pay a notable one for the Swiss market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.1yrs

Average management tenure


CEO

Dario Eklund (52 yo)

1.08yrs

Tenure

CHF1,605,770

Compensation

Mr. Dario Eklund has been Chief Executive Officer at Santhera Pharmaceuticals Holding AG since December 1, 2019. He served as Head of Global Business Operations at Vifor Pharma Ltd. since 2014. He served a...


CEO Compensation Analysis

Compensation vs Market: Dario's total compensation ($USD1.80M) is above average for companies of similar size in the Swiss market ($USD494.49K).

Compensation vs Earnings: Insufficient data to compare Dario's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Dario Eklund
Chief Executive Officer1.08yrsCHF1.61mno data
Thomas Meier
Founder & Director3.75yrsno data0.41%
CHF 223.8k
Andrew Smith
Chief Financial Officer0.75yrno datano data
Oliver Strub
Executive VP5.92yrsno datano data
Eva Kalias
Head of External Communicationsno datano datano data
Günther Metz
Head of Business Development & Executive VPno datano datano data
Shabir Hasham
Head of the Puldysa Global Programno datano datano data

1.1yrs

Average Tenure

57yo

Average Age

Experienced Management: SANN's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Thomas Meier
Founder & Director3.75yrsno data0.41%
CHF 223.8k
Martin Gertsch
Non-Executive Independent Director14.25yrsCHF274.09k0.19%
CHF 102.9k
Patrick V. J. Vink
Non-Executive Independent Director3.75yrsCHF219.27k0.0049%
CHF 2.7k
Elmar Schnee
Non-Executive Independent Chairman3.75yrsCHF296.31k0.059%
CHF 32.4k
Philipp Gutzwiller
Non Executive Independent Director3.75yrsCHF208.31k0.035%
CHF 19.2k

3.8yrs

Average Tenure

57yo

Average Age

Experienced Board: SANN's board of directors are considered experienced (3.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 82.8%.


Top Shareholders

Company Information

Santhera Pharmaceuticals Holding AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Santhera Pharmaceuticals Holding AG
  • Ticker: SANN
  • Exchange: SWX
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CHF54.844m
  • Shares outstanding: 20.31m
  • Website: https://www.santhera.com

Number of Employees


Location

  • Santhera Pharmaceuticals Holding AG
  • Hohenrainstrasse 24
  • Pratteln
  • Basel-Landschaft
  • 4133
  • Switzerland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SANNSWX (SIX Swiss Exchange)YesRegistered SharesCHCHFNov 2006
S3FDB (Deutsche Boerse AG)YesRegistered SharesDEEURNov 2006
SPHD.FOTCPK (Pink Sheets LLC)YesRegistered SharesUSUSDNov 2006
0QN1LSE (London Stock Exchange)YesRegistered SharesGBCHFNov 2006

Biography

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/16 18:11
End of Day Share Price2021/01/15 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.